At the 2024 ASH Annual Meeting, Dr. Syed Osman Ahmed contributed to a study investigating the incidence of sinusoidal obstruction syndrome (SOS) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) receiving inotuzumab ozogamicin (INO) followed by TBI-based allogeneic stem cell transplantation.
The retrospective analysis revealed that TBI-based conditioning, rather than alkylator-based regimens, may reduce the risk of SOS following INO therapy. Among twelve patients, only one developed SOS, and all remained alive at last follow-up highlighting a potentially safer strategy for high-risk patients.
This important work was made possible by a dedicated multidisciplinary team including Ahmed Alahmadi, Abdulrahman Nasiri, Sarah Samarkandi, Haya Alothaimeen, Marwa Nassar, Ali Alahmari, Ahmad S. Alotaibi, Mansour Alfayez, Hanan Alkhaldi, Ayman Saad, Amr Hanbali, and others.
Read the full abstract in Blood: https://lnkd.in/dqiNusFy
